📰 Sichern Sie News
Page 52 - Sichern Sie News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Sichern Sie. Real-time updates on events, politics, business and more.
March 24, 2023
LANCASHIRE HOLDINGS LIMITED - Director/PDMR Shareholding PR Newswire London, March 24 Lancashire Holdings Limited (the "Company") or ("LHL") Notification and public
March 24, 2023
Fidelity Special Values Plc - Compliance with Market Abuse Regulations PR Newswire London, March 24 Fidelity Special Values PLC ("the Company") Compliance with Market
March 24, 2023
Fidelity European Trust Plc - Monthly Summary PR Newswire London, March 24 Fidelity European Trust PLC LEI: 549300UC0QPP7Y0W8056 Monthly Summary as at 28 February
March 24, 2023
Invesco Investment Trusts - Net Asset Value(s) PR Newswire London, March 24 Invesco Perpetual UK Smaller Companies Investment Trust plc (IPU) As
March 24, 2023
Toronto, Ontario--(Newsfile Corp. - March 24, 2023) - Orefinder's Resources Inc. (TSXV: ORX) ("Orefinders" or the "Company") is pleased to announce that it will be seeking shareholder approval for the
March 24, 2023
EQS-News: MGI - Media and Games Invest SE / Key word(s): Miscellaneous MGI completes settlement of the 2027 Bonds and has reduced its leverage by repurchasing approx. EUR 55m of existing MGI
March 24, 2023
EQS Voting Rights Announcement: SGL CARBON SE SGL CARBON SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
March 24, 2023
An advanced new system for real-time video feed to incident commanders as events unfold, direct from observation scopes, drones and aircraft. Ottawa, Ontario--(Newsfile Corp. - March 24, 2023) - KWESST
March 24, 2023
Regulatory News: Celyad Oncology (Euronext Nasdaq: CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, is pleased
March 24, 2023
Emmanuel Hanon, PhD, will chair the company's scientific advisory board. Professor Peter Piot (MD, PhD) and Professor Patrick Soentjens (MD, PhD) have been appointed as advisors. Together, they bring complementary